The p53-null human lung cancer cell line H1299 was used in order to generate clones with ecdysone-inducible p53 as well as ecdysone-inducible p21 waf1 . Induced expression of p53 resulted in irreversible cell growth arrest with characteristics of replicative senescence, suggesting that p53 can prevent immortalization by activating a senescence program. The eect of induced p53 and p21 waf1 expression on the cytotoxic action of the anti-cancer drugs etoposide and cisplatin was also analysed. Whereas p21 waf1 overexpression conferred increased resistance to killing by either drug, p53 overexpression enhanced the cytotoxic eect of cisplatin but protected against etoposide cytotoxicity. These results imply that the impact of p53 on susceptibility to chemotherapy may depend greatly on the particular drug and type of DNA damage. Moreover, these data demonstrate the importance of using isogenic cell lines to address this issue.
Introduction
The tumor suppressor gene p53 is mutated in more than half of all human tumors (Greenblatt et al., 1994) and p53-de®cient mice are prone to multiple tumors at high frequency (Harvey et al., 1993a) , indicating the important role of p53 in preventing tumorigenesis (Lane, 1992; Levine, 1997) . Several cellular functions of wild type (wt) p53 were found responsible for this role. In response to radiation or genotoxic drugs, p53 mediates either growth arrest or apoptosis which prevent the replication of a mutated genome by either eliminating cells with DNA damage through programmed cell death or by allowing DNA repair to take place before DNA synthesis during S phase begins (for review see Gottlieb and Oren, 1996; Ko and Prives, 1996) . Although p53-mediated apoptosis may be considered a major avenue for avoiding cancer, recent studies on a mouse model of colon cancer indicate that loss of p53 does not correlate with reduced apoptosis and that wt p53 can retard the progression of adenoma to carcinoma by mechanisms other than apoptosis (Fazeli et al., 1997) . Such mechanisms may be related to p53-mediated growth arrest, particularly if this arrest becomes irreversible leading to replicative senescence (Smith and PereiraSmith, 1996; Atadja et al., 1995) . In this way, p53 may preclude illegitimate continuous cell replication and immortalization. The choice between apoptosis and growth arrest in response to p53 activation is not fully understood and depends on cell type and stage (Hansen and Oren, 1997) .
Cells derived from p53 de®cient mice readily become immortalized in culture and several reports implicate p53 in senescence of ®broblasts and other cell types (Harvey et al., 1993b; Tsukada et al., 1993; Bond et al., 1994 Bond et al., , 1996 Shay et al., 1991; Hara et al., 1991; Serrano et al., 1997) . Hence senescence may be an alternative mechanism for tumor suppression by p53. Indeed, a recent report demonstrated that p53 expression in the EJ human bladder carcinoma cell line leads to senescence (Sugrue et al., 1997) .
To further understand how p53 may regulate the choice between growth arrest or senescence versus apoptosis we used the p53 null lung cancer cell line H1299 to generate clones in which expression of either p53 or p21 waf1 can be induced by ecdysone . We report that induction of p53 overexpression in this system leads to irreversible growth arrest, accompanied by characteristic features of senescence.
The status of p53 also has important implications for the response of cells to chemotherapy. Recently, an extensive study of the response of 60 cancer cell lines of diverse origin to over 100 anti-cancer drugs revealed a signi®cant correlation between p53 integrity and chemosensitivity . Such conclusion requires veri®cation in isogenic systems consisting of the same cell line either expressing wt p53 or lacking p53 function. Here we analysed the eect of either induced p53 or p21 waf1 expression in combination with several anti-cancer drugs. We report that p53 may either antagonize or enhance drug-driven apoptosis, depending on the particular drug. On the other hand, p21 waf1 overexpression oered increased drug resistance irrespective of the drug. This system can be suitable for testing the eect of chemotherapy on isogenic cell populations diering only with regard to the presence or absence of wt p53.
Results

Ecdysone-induced expression of p53 and p21 waf1 in H1299 cells
We utilized the recently described ecdysone-inducible system to generate transcriptionallyinducible cell lines. The human lung cancer cell line H1299 (Takahashi et al., 1992) was chosen for this study since it is null for p53 owing to gene truncation (Bodner et al., 1992) . Moreover, transfection with p53 was shown to lead to growth arrest of these cells as analysed by inhibition of colony formation (Chedid et al., 1994; Zakut and Givol, 1995) . Ecdysone (muristerone)-inducible cell lines were generated in two steps. First, H1299 cells were transfected with pVgRXR followed by zeocine selection. Some 40 cell clones were isolated and transiently transfected with pIND/lacZ, maintained in the presence of muristerone and then stained with X-gal. Clone R-37 and R-38 were found to be the best inducible expressors of lacZ and were chosen for generating p53-expressing clones by transfection with pIND/p53 followed by G418 selection. Western blot analysis with the DO-1 antibody was used to screen for inducible p53 expression. Clones C-30 and C-48 were found to express high levels of p53 and were used in further experiments. In a similar way clone R-38 was transfected with pIND/p21 followed by G418 selection. This gave rise to clone W-65, which was chosen for further work. Figure 1A shows the induction of p53 expression by various concentrations of muristerone and Figure 1B depicts the time course of induction in the C-30 clone. The data indicate that the cells are not leaky for p53 and that maximum expression is obtained at 1 ± 2 mM muristerone. This level is obtained at approximately 6 ± 12 h after induction ( Figure 1B ), although significant p53 levels can be seen already as early as 3 h after induction with muristerone. The levels and kinetics of p53 expression correlate with the induction of endogenous p21 waf1 , a target for transcriptional upregulation by p53 ( Figure 1A and B). Analysis of mRNA expression in C-30 cells shows that the maximum levels of p53 and p21 waf1 mRNA are reached at 9 h and 12 h, respectively, after muristerone addition (data not shown). We also compared the level of induced p21 waf1 in C-30 cells with that obtained in the temperature-sensitive cell line H1299 Val135#3 and found that the transcriptional induction of p53 by muristerone in C-30 cells and the temperature-based activation of p53 in H1299 val135#3 cells resulted in similar p21 waf1 expression levels (data not shown). When muristerone-treated C-30 cells were subjected to immuno¯uorescent staining with antibody DO-1, approximately 90% of the cells stained for nuclear p53 after 12 h of muristerone induction (data not shown).
Clone W-65, expressing inducible p21 waf1 , was used to analyse muristerone-dependent induction of p21 waf1 as shown in Figure 1C and D. The levels of muristerone-induced p21 waf1 were found to be comparable to, and perhaps even slightly lower than those produced by the endogenous p21 waf1 gene in response to muristerone-mediated p53 induction (Figure 1 , compare A and B with C and D).
Growth arrest and senescence induced by overexpression of p53 in H1299 cells
The eect of induced p53 on C-30 cells grown in the presence of muristerone (2 mM) was analysed by several parameters. As shown in Figure 2 , p53 arrested the growth of C-30 cells in the presence of muristerone, while no growth arrest was seen in R-38 cells used as a control for non speci®c eects of muristerone. As shown below ( Figure 5 ), the arrest was associated with a modest increase in the fraction of cells found in the G2 phase of the cell cycle. To investigate the reversibility of the growth inhibition by p53, cells were incubated in the presence of muristerone for various time periods, and then muristerone was removed and the cells were allowed to grow again and form colonies. To that end, approximately 100 C-30 cells were plated in a 60 mm dish in the presence of muristerone. Muristerone was left in the culture for the number of days indicated in Figure 3 and was then replaced by regular culture medium. In each case, colonies were scored 10 days after removal of muristerone.
As is evident from Figure 3 , muristerone-mediated p53 induction irreversibly suppressed the ability of C-30 cells to form growing colonies. After four days in the presence of muristerone the number of recoverable clones was reduced to 25%, and after 10 days to only 9% of the number obtained in un-treated cultures. In contrast, no reduction in the number of clones was observed when the parent clone R-38 was treated with muristerone ( Figure 3A ). The irreversible arrest raised the possibility that excess p53 is driving H1299 cells into senescence. To test this notion more directly, the expression of the senescence associated marker b-galactosidase (SA-bgal) was monitored following p53 induction. SA-b-gal was shown previously to be associated with senescent cells in vitro and in vivo (Dimri et al., 1995) and is also induced in EJ cells with tetracyclin-regulated p53 (Sugrue et al., 1997) . As seen in Figure 4 signi®cant induction of this enzyme was found in C-30 cells cultivated for 4 days with muristerone. Therefore, similar to previous reports (Atadja et al., 1995; Smith and Pereira-Smith, 1996; Sugrue et al., 1997) , our results indicate that the growth inhibition of H1299 cells by p53 is at least in part irreversible due to replicative senescence. Interestingly, SA-b-gal activity was signi®cantly more prominent in cells treated with muristerone in the presence of 10% serum as compared to 0.5% serum (data not shown). Hence, it is conceivable that induction of senescence requires cooperation between p53 and some signals generated by serum factors. In conclusion, our results suggest that in addition to promoting growth arrest and apoptosis p53 can also drive cells into replicative senescence, thereby serving as a safeguard against cell immortalization.
Eect of p53 and p21
waf1 overexpression on the cellular response to anti-cancer drugs Extensive p53 overexpression has been shown to cause apoptosis in H1299 cells (Haupt et al., 1996; Chen et al., 1996; Kagawa et al., 1997) . In the two clones analysed by us, C-30 and C-48, we did not observe signi®cant p53-induced apoptosis and induction of p53 did not cause any detectable increase in the number of cells with sub-G1 DNA content ( Figure 5) . Hence, the extent of p53 induction in these clones is probably not high enough to elicit apoptosis in the absence of additional stimuli. The eect of muristerone (M) alone ( Figure 5A ) is slightly dierent between C-30 (p53 expression) and W-65 (p21 waf1 expression). In both cases there is an increase in the G1 population, whereas in p53 expressing line there is also an increase in the G2 population. The most important results of the growth arrest by both p53 and p21 is the marked reduction in the S phase population. This is similar to the result obtained with tetracycline-regulated p53 in H1299 cells (Chen et al., 1996) .
We next wished to study the eect of p53 overexpression on the cellular response to genotoxic agents. Two drugs with dierent mechanisms of action, etoposide and cisplatin (O'Connor et al., 1997), were chosen for this purpose. Treatment of uninduced C-30 cells with etoposide results in extensive apoptosis re¯ected by a dramatic increase in the sub-G1 fraction and disappearance of cells in the G1 phase ( Figure  5A) . Surprisingly, induction of p53 by muristerone concomitantly with etoposide treatment did not augment apoptosis, but rather resulted in a marked protection of C-30 cells against apoptosis. The sub-G1 fraction was reduced from 33% to 12% ( Figure 5A ). A similar picture was revealed by trypan blue staining of dead cells ( Figure 5B ). To ®nd out whether this protective eect might be related to the induction of p21 waf1 , we analysed also W-65 cells expressing inducible p21 waf1 . As shown in Figure 5 induction of p21 waf1 in these cells also provided protection against etoposide-mediated apoptosis; the sub-G1 fraction was reduced from 23 to 14% which was correlated in the reduction of the % of dead cells ( Figure 5B ). The similar behavior of C-30 and W-65 suggests that induction of p21 waf1 expression, either via p53 (in C-30) or directly by muristerone (in W-65) is responsible in both cell lines for protection against apoptosis.
A completely dierent eect of p53 overexpression was revealed when H1299 cells were exposed to cisplatin (CDDP). Treatment of C-30 cells with CDDP for 48 h resulted in a signi®cant extent of apoptosis as indicated by the accumulation of a substantial sub-G1 population (14.5%); approximately 28% of the cells were dead at this point as determined by trypan blue staining ( Figure 6B ) and con®rmed by propidium iodide uptake into non-permeabilized cells followed by FACS analysis (data not shown). As seen in Figure 6A , p53 overexpression increased signi®cantly the sub-G1 fraction in the CDDP-treated population (from 14.5 ± 34.6%). Similarly, the percentage of dead cells increased from 28 ± 41% ( Figure 6B ). Hence, in accordance with a recent drug screen report , wt p53 overexpression renders H1299 cells more sensitive to CDDP cytotoxicity. On the other hand, p21
waf1 overexpression had exactly the opposite eect and protected H1299 cells from CDDP-mediated cytotoxicity; the sub-G1 fraction was reduced from 13.7 to 4.1% ( Figure 6A ) and the percentage of dead cells went down from 25 to 12% ( Figure 6B ). These results suggest that whereas p21 waf1 has an antiapoptotic eect in both CDDP and etoposide treated cells, p53 may have opposing eects on the sensitivity to each of these drugs, conferring protection against etoposide cytotoxicity but enhancing CDDP cytotoxicity. It should be noted that the assay in this study was a short-term assay and it will be interesting to see if the protection from apoptosis is also seen in long-term colony survival assay. Our ®ndings demonstrate the Figure 4 SA-b-gal staining of C-30 cells induced to express p53. C-30 cells were seeded at a density of 2610 5 cells per 100-mm dish and 12 h later the medium was replaced with a medium containing 2 mM muristerone (A) or without 2 mM muristerone (B). Four days later the cells were washed, ®xed and stained for SA-b-gal (Dimri et al., 1995) for 16 h and then photographed using a Zeiss axiophot microscope value of isogenic cell lines for testing the eect of p53 on the response to chemotherapy, and indicate that the eect of p53 on the outcome of anticancer drug treatment may depend on the particular choice of drugs, as well as on cell type and endogenous p53 levels.
Discussion
In this study, we have used the recently described ecdysone-regulated expression system to study the eect of conditional expression of either p53 or p21 waf1 in human H1299 lung adenocarcinoma cells. Previous studies using a temperature sensitive p53 mutant in rodent ®broblasts revealed that the growth arrest conferred on cells by induction of wt p53 activity at 328C was reversible (Michalovitz et al., 1990; Martinez et al., 1991) . By contrast, the growth arrest conferred by p53 on H1299 cells was found to become largely irreversible within 2 ± 4 days of p53 overexpression, as measured by inhibition of colony formation (Figure 3) . Moreover, the growth arrested cells exhibit characteristic features of senescence. These dierent eects of p53 may be partially explained by the use of dierent cell types. For instance, induction of p53 by DNA damage causes only a transient cell cycle arrest in rodent ®broblasts, but a permanent arrest in human ®broblasts (Linke et al., 1997) .
The extent of p53 overexpression can also be a crucial determinant of the biological outcome. Experiments making use of tetracycline-regulated p53 expression in H1299 cells have demonstrated that the level of p53 expression can determine whether the cells will undergo apoptosis (high p53 expression) or growth arrest (low p53 expression) (Chen et al., 1996) . Similar conclusions were reached in a study using recombinant p53 expressed from a vaccinia virus (Ronen et al., 1996) . In our study, no evidence of apoptosis was observed in response to muristerone-induced p53 5 cells/100 mm dish. After 8 h the medium was replaced to contain etoposide (5 mM) with or without muristerone (2 mM). After 48 h¯oating cells were collected, spun down and combined with trypsinized adherent cells. The cells were resuspended in a total volume of 1 ml, of which 50 ml was used for trypan blue staining and dead cell counting while the rest was used for cell cycle analysis in the FACS. Induction of senescence in human tumor-derived cells by p53 overexpression was also reported by Sugrue et al., (1997) , using the bladder carcinoma EJ cell line. Such p53-mediated senescence may be an important mechanism to prevent cells from progressing to a state of unlimited proliferation, thereby serving as a viable alternative to apoptosis. Conversely, loss of p53 function would favor continued cell proliferation, a conclusion supported by the fact that ®broblasts from p53-de®cient mice more readily become immortalized in culture (Tsukada et al., 1993; Bond et al., 1994) . Therefore, along with growth arrest and apoptosis, replicative senescence may be considered as an additional distinct mechanism through which p53 can exert its tumor suppressor function. Unlike the transient growth arrest induced by p53 in certain cell types, induction of senescence implies that such cells will remain excluded from the replicative pool even when the stress signal which triggered the p53 response is over. In cells which have a relatively limited DNA repair capacity or are approaching the end of their replicative lifespan anyway, it may be safer to opt for irreversible senescence rather than take the risk of reentering the cell cycle with only partially repaired damage. The broad relevance of senescence to p53-mediated tumor suppression is also suggested by a recent study on colon cancer in mice (Fazeli et al., 1997) .
The inducible p53 system allows a comprehensive analysis of the relationship between p53 expression and the cellular response to DNA damage caused by anticancer drugs. This matter is of great potential importance because of its relevance to the making of cancer chemotherapy decisions. Since changes in p53 are common in human tumors, it is obvious that the detailed understanding of the relationship between p53 status and drug sensitivity is required in order to make better choices of chemotherapy. A recent study by the Developmental Therapeutic Program of the National Cancer Institute (O'Connor et al., 1997), using 60 cell lines and 123 standard anti-cancer drugs, revealed that mutant p53 cell lines tend to be less sensitive than wt p53 lines to most drugs (e.g. cisplatin and 5-uoroaracil). Our results using two drugs (etoposide and cisplatin), which operate through dierent mechanisms, show that in the case of cisplatin p53 indeed markedly increases the cytotoxic eect of the drug on H1299 cells. This eect might have been even more pronounced in the absence of p53-mediated p21 waf1 induction (see Figure 1) , since induction of p21 waf1 alone (in W-65 cells) actually results in chemoprotection. It is thus conceivable that the enhancing eect of p53 on cisplatin-induced cytotoxicity will be particularly potent in tumor cells in which p21 waf1 induction either does not occur eciently or is functionally ineective (e.g. when Rb is mutated). Indeed cells lacking p21 waf1 exhibit increased sensitivity to cisplatin as well as to several other anti-cancer agents .
In contrast to its pro-apoptotic contribution in the context of cisplatin treatment, p53 actually has a protective eect against etoposide-induced cell death.
This observation is at ®rst glance very surprising, as it appears inconsistent with the general notion that the presence of wt p53 renders tumor cells more sensitive to killing by DNA damaging agents (Lowe, 1995) . However, there are already precedents for an antiapoptotic eect of p53 in tumorigenic cells treated with certain chemotherapeutic agents (Malcomson et al., 1995; Vikhanskaya et al., 1995 Vikhanskaya et al., , 1996 and even in mouse ®broblasts (Lassus et al., 1996) . Remarkably, the protective eect of p53 against etoposide-induced death is similar to that seen with p21 waf1 overexpression. It is thus conceivable that this protective eect of p53 is largely, if not completely, due to the induction of p21 waf1 expression, since the levels of p21 waf1 achieved in C-30 cells are comparable to those found in muristerone-treated W-65 cells (Figure 1 ) which exhibit a similar extent of etoposide resistance ( Figure 5 ). This is also in line with the demonstration that p21 waf1 protects against apoptosis (Polyak et al., 1996) and loss of p21 waf1 potentiates apoptotic response induced by intrinsic or extrinsic means (Wang et al., 1997) . The fact that there exists, nevertheless, a generally good correlation between p53 function and higher tumor chemosensitivity (Lowe, 1995) could be due to the existence of additional mutations in the pRb pathway in such tumors. If this pathway becomes defunct, either owing to Rb gene alterations or to mutations in upstream regulators of pRb activity, induction of p21 waf1 by p53 may have no practical consequences. In that case, the only contribution of p53 activation will be to promote apoptosis, either through other target genes or through mechanisms independent of p53-speci®c transcriptional activation (Hansen and Oren, 1997) .
The pro-apoptotic eect of p53 is revealed with cisplatin, but not with etoposide. The DNA damage induced by cisplatin, but not by etoposide, is recognized and repaired by the nucleotide excision repair (NER) machinery. In this respect, it is of note that the XPB and XPD helicases, central components of the NER machinery, interact directly with p53 and have been shown to play an important role in p53-mediated apoptosis (Wang et al., 1996) . The enhanced eect of p53 on cisplatin-induced apoptosis might therefore be due to a death promoting activity elicited only by drugs which promote interactions between p53 and the NER machinery.
In conclusion, our ®ndings imply that the status of p53 may have dierent and even opposing eects on the cellular response to anti-cancer agents. Therefore, when evaluating cancer patients one cannot make simple generalized predictions about the relationship of p53 status to therapy outcome. Obviously, ability to make such predictions will require a more systematic analysis of experimental model systems, comparing dierent cell types and dierent drugs. In such analysis, isogenic cell lines of the type described here are likely to prove valuable.
Materials and methods
Cell culture
The H1299 human lung adenocarcinoma (Takahashi et al., 1992) was maintained in RPMI containing 10% fetal bovine serum (FBS). H1299-pVgRXR cells were maintained in the same medium containing zeocin (100 mg/ml). The H1299-p53 and H1299-p21 waf1 cell lines were maintained in medium containing zeocin and G418 (400 mg/ml). To induce p53 or p21 waf1 expression, muristerone (a synthetic analog of ecdysone), was added to the medium (®nal concentration 2 mM). Growth curves were obtained from cell counts in the presence or absence of muristerone. Log-phase cells were seeded at a density of 10 5 cells/60 mm dish, and cells were counted for 5 days at 24 h intervals. The following cell lines were used in this study: R-38, H1299 transfected with pVgRXR expressing the ecdysone receptor; C-30, H1299 (R-38) transfected with pIND/p53 expressing human wt p53; W-65, H1299 (R-38) transfected with pIND/p21 expressing human p21 waf1 and H1299 Val135#3, a derivative of H1299 expressing a temperature sensitive mouse p53 mutant (S Wilder and M Oren, unpublished).
Plasmids and transfections
Plasmids pVgRXR, pIND and pIND/lacZ were from Invitrogen (San Diego, CA, USA). pIND/p53 was prepared by cloning the HindIII/XbaI fragment of human wt p53 cDNA (1.3 kbp, gift of Dr T Unger) into pIND. pIND/p21 was prepared by cloning the 0.5 kbp BamHI/ EcoRI fragment of human p21 waf1 cDNA (Chedid et al., 1994) into pIND. H1299 cells were transfected with each plasmid using the calcium phosphate method. Clone selection was with zeocin (100 mg/ml) for pVgRXR and with G418 (400 mg/ml) for pIND/p53 or pIND/p21. Stable clones obtained by double selection were screened by immunoblotting using antibody DO-1 for p53 and C-19 (Santa Cruz) for p21 waf1 .
Immunoblot analysis
Total cell lysates were prepared by standard methods (Sambrook et al., 1989) and protein content was determined with the Bio-Rad protein assay kit (Bio-Rad). Samples containing 50 mg total protein were subjected to either 10 or 15% SDS/PAGE and transferred to nitrocellulose membranes (BA.85, Schleicher and Schuell). The ®lter was blocked in 2.5% skim milk/0.1% Tween 20 in PBS for 30 min followed by incubation with the speci®c antibody and detection with HRP goat anti-mouse IgG for DO-1 (Sigma) or goat anti rabbit IgG (Jackson Laboratories) for C-19, followed by ECL (Amersham).
Cell staining
Immunostaining for p53 was performed on cells grown on coverslips. The coverslips were washed with PBS, ®xed with cold methanol for 30 min at 7208C and stored in PBS at 48C. Cells were stained for p53 with the DO-1 monoclonal antibody, followed by rhodamine-labelled goat anti-mouse IgG (Sigma). Senescence-associated b-gal (SAb-gal) staining was at pH6.0 as previously described (Dimri et al., 1995) . Cells (2610 5 ) were seeded in 100 mm dishes and after 12 h the medium was replaced with muristerone (2 mM)-containing medium. Four days later, the dishes were washed with PBS and ®xed with 3% formaldehyde in PBS for 5 min at room temperature followed by one wash in PBS and stained for 16 h at 378as described (Dimri et al., 1995) .
Colony staining
Cells were seeded at a density of 100 cells per 60 mm dish and maintained with or without muristerone for varying periods. After withdrawal of muristerone the cultures were maintained for 10 more days. Colonies were stained by addition of 0.5 ml crystal violet solution for 30 min followed by washing, as previously described (Zakut and Givol, 1995) .
Cell cycle analysis
Cells (5610 5 ) were seeded on 100 mm dishes and 12 h later the medium was replaced by medium containing cisplatin (2.5 mg/ml) in the presence or absence of muristerone (2 mM). After 48 h the¯oating cells were collected and the attached cells were trypsinized, collected and added to thē oating cells. Cells were similarly treated with etoposide (5 mM) in the presence or absence of muristerone. The cells were centrifuged, washed in PBS, resuspended in 1 ml PBS, ®xed in 5 ml of cold methanol for 30 min at 7208C, centrifuged again, washed once with PBS and resuspended in 1 ml PBS containing 50mg/ml of RNase and 50mg/ml propodium iodide (Sigma), and then analysed in ā uorescence-activated cell sorter (FACSORT, Becton Dickinson). Data were analysed using the Cell®t program.
Northern blot analysis
Total RNA was isolated by the TRIzol reagent (GIBCO ± BRL), according to the manufacturer's protocol. RNA was stored under ethanol. Aliquots containing 15 mg RNA were electrophoresed through a 1%-agarose-formaldehyde gel and transferred to a nylon membrane (Hybond N + , Amersham) followed by UV crosslinking in an autocrosslinker (Stratagene). Hybridization probes, labeled with 32 P, were prepared using the Rediprime random primer labeling kit (Amersham). Hybridization was in 56SSPE, 56Denhardt's solution and 0.5% SDS at 658C. The ®nal washing was in 0.16SSC, 0.1% SDS at 658 for 10 min.
